Badreddin Edris
CIK 1786966 · Chief Operating Officer · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.66M
Companies
2
Total Filings
28
Lifetime Open-Market Net
-$13.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EWTX | Director | 61,209 | $43.52 | $2.66M | -$3.40M | 6 | 2026-06-16 |
| SpringWorks Therapeutics, Inc. (SWTX) Delisted | Chief Operating Officer | 0 | $46.99 | $0 | -$10.55M | 18 | 2025-07-02 |
Recent Filings · Page 2 of 3
28 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-12-05 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −20,000 | -$839.3K | EDGAR |
| 2024-09-04 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −20,000 | -$813.0K | EDGAR |
| 2024-09-03 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Notice (144) | −50,000 | -$2.09M | EDGAR |
| 2024-06-12 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2024-06-05 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Sell (S) | −20,000 | -$801.4K | EDGAR |
| 2024-06-03 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Notice (144) | −50,000 | -$2.07M | EDGAR |
| 2024-01-08 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Mixed | +32,377 | -$396.6K | EDGAR |
| 2023-06-14 | EWTX | Grant (A) | — | $0 | EDGAR |
| 2023-01-10 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Tax (F) | −1,483 | -$39.2K | EDGAR |
| 2023-01-09 | SpringWorks Therapeutics, Inc. (SWTX) Delisted | Mixed | +30,668 | -$91.5K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.